Storage diseases because of lysosomal enzyme deficiencies may be treated by the transplantation of cells that secrete the enzyme which is deficient in patients. One can expect that increasing the amount of secreted enzymes will improve the therapy efficacy. Secretion of lysosomal enzymes can be enhanced by reducing the mannose 6-phosphate receptor involved in the lysosomal sorting of newly synthesized lysosomal enzymes. For this purpose, we have constructed hammerhead ribozymes targeting the mRNA of the large murine mannose 6-phosphate receptor (M6PR300). In vitro ribozymes cleave M6PR300 RNA fragments efficiently with cleavage rates of 69-93% after 3 h of incubation. Ribozymes were cloned into an expression vector in which they are integrated into the VaI adenovirus RNA to increase stability and in which they are transcribed from an RNA polymerase III promoter. These plasmids were transiently transfected into BHK cells to investigate in vivo activity. Two ribozymes reduce efficiently the levels of murine M6PR300 mRNA in transient transfection experiments to 42-45%. This correlates with the reduction of M6PR300 biosynthesis, which is reduced also to 37% of normal. We can also demonstrate that the reduction in M6PR300 is sufficient to increase a lysosomal enzyme secretion.
Introduction
Lysosomal enzymes are synthesized at the rough endoplasmic reticulum, where they cotranslationally acquire N-linked oligosaccharide side chains. In the Golgi apparatus, soluble lysosomal enzymes are specifically recognized by a phosphotransferase, which initiates a two-step process, which results in the phosphorylation of position 6 of mannose residues of the N-linked oligosaccharide side chains. Via these mannose 6-phosphate (M6P) residues lysosomal enzymes can bind to mannose 6-phosphate receptors (M6PR), which mediate the further vesicular transport from the Golgi apparatus to the lysosome. 1 In mammalian cells, two receptors of different molecular weights exist. Both M6PRs are transmembrane glycoproteins and recycle between the trans-Golgi network, the plasma membrane and the endosomal compartment. The cation-dependent (CD-) M6PR has an apparent molecular weight of 46 000 (M6PR46) and the cation-independent (CI-) M6PR of 300 000 (M6PR300).
1,2 Both receptors bind different but overlapping subsets of lysosomal enzymes. 3 The binding of newly synthesized lysosomal enzymes to the receptors in the Golgi compartment is never complete. A considerable fraction of these enzymes escapes receptor binding and is secreted from the cells.
However, the secreted enzymes can be recaptured, since the M6PR300 receptor is not only found in the Golgi apparatus but is present also on the plasma membrane and mediates the endocytosis of lysosomal enzymes. Thus, this receptor also functions in the transport from the plasma membrane to the lysosome. 1 Lysosomal enzyme deficiency can cause various diseases, termed lysosomal storage disorders. Owing to the particular sorting pathway of soluble lysosomal enzymes, these diseases are suitable candidates for enzyme replacement and gene therapy. Enzymes bearing M6P residues can be injected, endocytosed by the enzyme-deficient cells of the patient and correct the metabolic defect. 4 Alternatively, cells expressing the missing enzyme can be transplanted. The secreted fraction of this enzyme will be available for endocytosis by the M6PR pathway. It can be expected that this therapy will be more efficient, the more enzyme the transplanted cell secretes. This can be achieved by two means: (i) by increasing the synthesis of the enzyme via genetic modification and (ii) by increasing the secretion via downregulation of the M6PRs, which would enhance the secreted fraction of newly synthesized M6P-bearing lysosomal enzymes. 5 Thus, tools that would allow reduction of M6PRs synthesis could be of general value in gene therapy of lysosomal storage diseases. One means to achieve this is the expression of ribozymes to cleave the M6PR mRNA, which should lead to the reduction of receptor synthesis.
Ribozymes are small catalytic RNA molecules, which are attractive therapeutic agents. The best characterized examples of ribozyme-catalyzed cleavage reactions are found in plant viroids, virusoids and linear satellite RNAs. 6 The small, self-cleaving RNAs have conserved catalytic core sequences, and need a metal-hydroxide that is involved in the cleavage reaction. 7 The cleavage reaction, which is very specific, generates 2 0 ,3 0 -cyclic phosphate and 5 0 -OH products. These self-cleaving RNAs can be subdivided into groups depending on the sequence and secondary structure formed around the cleavage site. The most studied types are the hammerhead and hairpin ribozymes. The hammerhead structure consists of three base-paired stems (helices I, II and III) (Figure 1 ). The catalytic domain of the ribozyme includes highly conserved nucleotides and is essential for ribozyme activity. Two stretches of oligonucleotides, which give the hammerhead construct its specificity, flank the central core of the ribozyme. The target site of the ribozyme can be any NUH sequence (where H¼A, C or U, and N is any nucleotide). 8 Hammerhead ribozymes require a divalent metal ion, such as Mg 2+ , to mediate catalytic cleavage. 9 In this work, we have constructed specific ribozymes directed at the murine M6PR300 mRNA with the aim to develop therapeutic tools for improved secretion of lysosomal enzymes from transplanted platform cells.
Results

Construction of specific hammerhead ribozymes
In order to identify potential ribozyme cleavage sites of murine M6PR300 mRNA, predictions of the secondary structure of M6PR300 RNA fragments were generated by the program MFOLD (Figure 2a) . 10, 11 A comparison of cleavage rates of individual NUH triplets revealed that the reaction rates decrease in the following order: GUC4CUC4AUU4GUU. 12 Accordingly, we chose only GUC and CUC cleavage sites, which were located in putative loop structures of the murine M6PR300 mRNA, since single-stranded loop structures are more likely to be accessible by ribozymes. This led to the identification of four potentially single-stranded GUC and three CUC sites. We constructed four ribozymes designated as Rz A, Rz B, Rz C, Rz D to target the GUC sites and Rz E, Rz F, Rz G to target the CUC sites, respectively (Figure 2b ). The catalytic domain of the ribozymes was identical, the specificity for the potential target sites is provided by two short antisense regions, flanking the target sites at the 5 0 -and 3 0 -end, respectively. These regions are 7-8 nt long in the case of Rz A, B, C, D, F, G and 8-15 nt in the case of Rz E.
The ribozyme coding cassettes were cloned into vector pGval (kindly provided by A Lieber). 13 Here they are embedded in the vaRNA I gene of human adenovirus type 2, which can form a stable secondary structure and is highly resistant against nuclease degradation.
The plasmid contains the T7 promoter for in vitro transcription and a pol III promoter for in vivo expression of ribozymes. 13 Ribozymes cleave murine M6PR300 RNA in vitro
We examined the potential of ribozymes to cleave murine M6PR300 RNA in vitro. The size of mouse M6PR300 mRNA (8.8 kb) excludes that the entire mRNA is used as a ribozyme substrate in vitro. Thus, fragments of the M6PR300 cDNA encompassing the potential ribozyme cleavage sites were subcloned into the Bluescript II SK +/À plasmid (Stratagene). These were linearized with HindIII restriction enzyme and transcribed in vitro. The RNA fragments, which were designated as sA, sB, sC, and sD, were labelled with [g- (Figures 3 and 4 ). An experiment, in which the cleavage reactions were done for varying length of time revealed extensive cleavage after 3 h of incubation of M6PR300 RNA fragments sD (93.5% cleaved), of sC (80.5%) and 69% of sB ( Figure 4 ).
Effects of ribozymes on M6PR300 synthesis
Since the ribozymes are specific for the murine receptor, we initially transfected NIH/3T3 and other murine cell lines (Swiss 3T3, murine embryonic fibroblasts) with the ribozymes to investigate the reduction of the endogeneous M6PR300 mRNA and protein. However, although we applied various transfection reagents and protocols, we were not able to transfect more than 20% of this murine cells. If the ribozymes reduce the endogeneous M6PR300 mRNA by about 50% this would result in an overall reduction of mRNA by not more than 10%. This small difference cannot be reliably detected in Northern blot analysis.
Cotransfection, however, of murine M6PR300 cDNA and ribozyme expressing plasmids into BHK cells overcomes this problem. First, the endogeneous hamster M6PR300 mRNA is not detected in the Northern blot under stringent washing conditions, thus there is no endogeneous M6PR300 mRNA background. Second, in our transfection protocol we can transfect 60-70% of BHK cells. Therefore, we cotransfected the cDNA Figure 1 The secondary structure model of the trans-acting hammerhead ribozyme (Rz B). The arrow indicates the predicted site of cleavage at nucleotide 2130. All constructed ribozymes in this study contained the same catalytic core (II). Stems I and III contain the recognition site for each ribozyme.
Hammerhead ribozymes reduce synthesis of M6PR300
A Yaghootfam and V Gieselmann expressing the murine M6PR300 mRNA with the ribozymes into BHK cells.
To investigate the potential of the ribozymes to reduce M6PR300 mRNA in vivo, 50 ng pBEH plasmid containing the complete murine M6PR300 cDNA downstream of the SV 40 early promoter, and 2 mg pGval vectors containing different ribozyme cassettes downstream of the Pol III promoter were cotransfected into BHK-21 cells. At 48 h after transfection, cells were lysed, and total RNA was isolated. A Northern blot of total RNA was hybridized with a mouse M6PR300 cDNA probe (Figure 5a ). Transcripts of ribozyme cassettes were detected with a radioactively labelled oligonucleotide hybridizing to the catalytic domain of the hammerhead ribozymes ( Figure  5b ). Only two of seven ribozymes (Rz B and Rz D) caused a reduction of murine M6PR300 mRNA in transfected cells.
Rz A, Rz C, Rz E, Rz F, and Rz G did not decrease M6PR300 mRNA level in transfected cells. Both the ribozymes, which reduce M6PR300 mRNA in eucaryotic cells to 42 and 45% of control (Figure 5c ), respectively, target sites within the translated region of the murine M6PR300 mRNA.
Ribozymes affect the biosynthesis of M6PR300
We further investigated whether the ribozymes reducing mouse M6PR300 mRNA in vivo also cause a reduction of M6RP300 synthesis. BHK-21 cells were transiently transfected with plasmids encoding the mouse M6PR300, and the hammerhead ribozyme cassettes. At 48 h after After pulse labelling cells were lysed, M6PR300 was immunoprecipitated from the lysates and analyzed by autoradiography (Figure 6a ). The amount of synthesized M6PR300 was quantified using a phosphoimager BAS 1000 (Fuji). Results of four different experiments are shown in Figure 6b . These experiments show that synthesis of murine M6PR300 can be reduced to 37% of control levels by Rz B and 62% by Rz D, respectively (Figure 6b ).
Effects of ribozymes on secreation of arylsulfatase A
To demonstrate an effect of ribozymes in vivo, we choose the MEF-mpr46 cell line. These cells are deficient in the small 46 kDa M6PR46 and only express the large M6PR300.
14 Since the transfection efficiency of these cells is only about 10%, we used an assay in which ribozymes and the cDNA of human lysosomal arylsulfatase A encoding plasmids were cotransfected into MEFmpr46 cells. Since transfected cells receive both the ribozyme and the cDNA of a lysosomal enzyme, a ribozyme-induced reduction of the amount of endogeneous M6PR300 in the transfected cells should enhance the secretion of this lysosomal enzyme. As a lysosomal enzyme, we used human ASA since a monoclonal antibody specific for the human enzyme allows to measure selectively the human enzyme in the massive background of endogenous murine sulfatases that are secreted by all transfected as well as untransfected cells. 15 Thus, human ASA was immunoprecipitated with the monoclonal antibody from cells and media of cells which were cotransfected with Rz B, Rz D and an irrelevant ribozyme (Rz Co). Enzyme activity was determined in the immunoprecipitates of cells and media. Cells expressing the irrelevant control ribozyme (Rz Co) secrete about 15% of human ASA, whereas this amount is increased to 25% in cells transfected with Rz B (Figure 7 ). Rz D is less effective, which is in accordance with M6PR300 biosynthesis experiments, in which this ribozyme was less effective in reducing the amount of receptor.
Discussion
Lysosomal storage diseases are good candidates for enzyme replacement and gene therapy approaches. This is because of M6P residues, which play a central role in efficient endocytosis and delivery of lysosomal enzyme Reactions were subjected to denaturing gelelectrophoresis and autoradiography. sA, sB, sC, and sD depict the uncleaved M6PR300 RNA fragments. nt gives the length of the substrate fragments, respectively. Figure 4 Time dependence of ribozyme cleavage reactions. Ribozymes were incubated under conditions described in Figure 3 with M6PR300 RNA fragments. Reactions were terminated after 15, 30 , 60, 120, and 180 min. Cleavage reactions were subjected to denaturing gelelectrophoresis and autoradiography. The relative amount of the cleavage product was quantified with a Fuji phosphoimager BAS 1000 (Fuji). Top panel summarizes the data for all ribozymes tested. An example of the reaction of Rz C is shown at the bottom. nt gives the length of sC and cleavage product, respectively.
Hammerhead ribozymes reduce synthesis of M6PR300
A Yaghootfam and V Gieselmann from the extracellular space to the lysosomes. Genetically modified cells, which are transplanted for therapeutic reasons, secreting the enzyme that the respective patient is missing, can be expected to be more efficient, the more enzyme they secrete. The amount of secreted enzyme can either be enhanced by overexpression or by interference with the intracellular sorting events of lysosomal enzymes in the transplanted cell. Both approaches are a means to improve the bioavailability of all lysosomal enzymes sorted in an M6P-dependent way. Here we have constructed seven hammerhead ribozymes, which target the large murine M6PR300 mRNA. This receptor functions in the sorting of lysosomal enzymes from the Golgi apparatus to the lysosomes. Deficiency of the receptor in fibroblasts of mice has been shown to cause enhanced secretion of newly synthesized lysosomal enzymes. 16, 17 We have used RNA structure predictions of fragments of the M6PR300 RNA to identify singlestranded GUC-or CUC-containing sites, which are considered to be preferential targets for ribozyme cleavage.
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Four GUC-targeting ribozymes were tested for their capability to cleave M6PR300 RNA fragments in vitro, three of which proved to be very efficient, whereas one showed no cleavage activity. Nevertheless, all ribozymes were tested in cultured cells since it was recently shown that in vitro activity and in vivo activity of ribozymes does not correlate. 18 The latter is most likely because of the fact that in vivo the substrate binding rather than the cleavage reaction is the rate-limiting step. The experiments we performed in cultured cells clearly revealed that the two ribozymes had the capacity to reduce mouse M6PR300 mRNA levels in cultured cells to about 40% of control. In accordance with these data, the two Hammerhead ribozymes reduce synthesis of M6PR300 A Yaghootfam and V Gieselmann ribozymes reduce the biosynthesis of the murine M6PR protein to 37 and 62% of normal in the BHK cell ( Figures  5 and 6) .
Thus, these results clearly demonstrate that reduction of M6PR biosynthesis by a ribozyme-mediated approach is possible. This approach is particularly suitable for the treatment of diseases because of the deficiency of sulfatases, like mucopolysaccharidosis VI, Morquio disease, metachromatic leukodystrophy and others. Proper function of sulfatases depends on a sulfatase-specific post-translational modification. 19 This modification, which takes place in the endoplasmatic reticulum, converts a cysteine residue in the active center into a formylglycine residue. 19 In the case of overexpression, one sulfatase competes with the modification of others, indicating that the post-translational modification is the step limiting the amount of active sulfatases that can be expressed by a cell. 20 In these cases, secretion by transplanted cells needs to be enhanced by an approach other than massive overexpression, namely interference with intracellular sorting of lysosomal enzymes in the transplanted cell. Using arylsulfatase A as an indicator enzyme we could indeed demonstrate that ribozymeinduced reduction of M6PR300 synthesis enhances the secretion of this enzyme by a factor of about 1.7.
The reduction of M6PR300 will not only enhance the secretion of an overexpressed enzyme, but also the secretion of all lysosomal enzymes synthesized by the transplanted cell. So far there have been no reports that overexpression or the enhanced secretion of lysosomal enzymes have any adverse side effects. In particular for arylsulfatase A, this has been excluded. 21 Thus, the combination of genetic modification and ribozymeinduced receptor reduction seems to be a suitable approach for lysosomal storage diseases.
It can also be expected that the downregulation of the M6PR300 does not affect the life cycle of the modified cell. Since M6PR300-deficient cells can be grown in tissue culture without special requirements, severe side effects affecting the survival of such cells cannot be expected. It was reported recently that in M6PR300-deficient cells lysobisphosphatidic acid accumulates in the late endosomal/lysosomal compartment. 22 A similar phenomenon has also been described for cells from patients with various forms of glycolipidosis. 23 Since these cells can also be cultured in vitro and so far no toxic effects of lysobisphosphatidic acid have been described, it seems unlikely that this compound reduces the fitness of the modified cell. It should also be taken into account that ribozymes will not allow to generate a complete reduction of the murine M6PR300, such that putative adverse effects in ribozyme-modified cells can be expected to be milder than in completely deficient cells.
In summary, the ribozyme-induced reduction of M6PR biosynthesis may prove applicable to enhance the bioavailablity of lysosomal enzymes in the treatment of lysosomal storage diseases, in particular for sulfatase deficiencies.
Materials and methods
Ribozyme and substrate construction
Mouse wild-type M6PR300 cDNA (kindly provided by P Lobel) was subcloned into the expression vector pBEH (Artelt) , resulting in the plasmid pBEH-M6PR300. [24] [25] [26] For the construction of plasmids that encode ribozyme cassettes, overlapping sense and antisense oligonucleotides encompassing the catalytic domain were designed. NsiI and XhoI restriction sites were included at the 3 0 -and 5 0 -end, respectively. All of the ribozyme cassettes have a size of 44 bp, except of the Rz E, which has a size of 52 bp (Figure 8 ).
After annealing, the double-stranded oligonucleotides were digested with XhoI (5 0 -end) and NsiI (3 0 -end) and cloned into the SalI and PstI sites of pGval plasmid (kindly provided by A Lieber and M Strauss). This vector has a T7 and Pol III promoters allowing for both in vitro and in vivo transcription. 13 In vitro transcription reactions and 5 0 -labelling of RNA Transcription reactions of linearized ribozyme plasmids (with HindIII) were carried out with T7 RNA polymerase as described. 29 Transcription reactions of the M6PR300 cDNA fragments were initiated in the presence of 100 mM each NTP (ATP, UTP, CTP and ApG), 2 mg of linearized plasmid template and 20 U T7 RNA polymerase. After incubating the reaction at 371C for 10 min, 100 mM GTP was added and the reaction proceeded for another 2 h.
In vitro cleavage reaction
Single-turnover cleavage reactions of hammerhead ribozymes were performed by incubating 0.66 pmol 5 0 -[ 32 P]M6PR300 RNA fragments, 1.32 pmol of in vitro transcribed ribozymes in 50 mM Tris/HCl (pH 7.5). All reactions were performed at 421C. The mixtures of substrate, ribozyme and buffer were heated to 421C, finally 10 mM MgCl 2 was added. The cleavage reactions were terminated by ethanol precipitation. Fragments generated in the reactions were separated on an 8% polyacrylamide/8 M urea gel and visualized by autoradiography.
Transfections
The hamster kidney cell line BHK-21 and the murine fibroblast cell line NIH/3T3 were maintained in Dulbecco's modified Eagle medium (DMEM) with 4.5 g/l glucose, 3.7 g/l NaHCO 3 , 10% (v/v) heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (Invitrogen s ) in a humidified atmosphere containing 5% CO 2 /95% air at 371C.
Plasmids were purified by CsCl gradient centrifugation. 30 For transient transfections, 2 Â 10 6 BHK-21 cells were seeded on 6-cm dishes and grown overnight. Cells were transfected with circular plasmids of pBEH-M6PR300 (50 ng/dish), pGvalRz (2 mg/dish) and secreted alkaline phosphatase (SEAP) (100 ng/dish) using the Lipofectamin Plust protocol as provided by the manufacturer (Invitrogen s ).
Extraction of total cellular RNA
Transfected BHK-21 cells were lysed 48 h post-transfection by the addition of 0.6 ml/dish of lysis buffer containing 200 mM sodium acetate (pH 4.0), 4 M guanidium isothiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sodium N-lauryl-sarcosyl and 0.1 M b-mercaptoethanol. 31 The lysate was extracted once with phenol followed by one extraction with chloroform. Total cellular RNA was obtained after precipitation with ethanol. The RNA pellets were washed once with 70% ethanol and resolved in DEPC-treated water.
Northern blot analysis of M6PR300 mRNA Total RNA (6 mg) isolated from transfected cells and 40 mg isolated from NIH/3T3 cells were separated in a 1% denaturing agarose gel. After the transfer of RNA to a Hybond-N + membrane (Amersham Pharmacia), the membrane was hybridized with an [a- 32 P]dCTP labelled cDNA probe encompassing nucleotides 450-1900 of the M6PR300 cDNA. Labelling and hybridization conditions have been described. 32 A glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe was used as reference for quantitation for M6PR300 mRNA. Autoradiographs were performed at different exposure times with hyper films (Kodak) at À801C.
Northern Blot analysis of ribozyme mRNA
Total RNA (8 mg) isolated from transfected cells were loaded on a 2% denaturing agarose gel and transferred to a Hybond-N + membrane. For the detection of ribozyme mRNA, an oligonucleotide (10 pmol) containing the catalytic domain of the ribozyme cassette (5 0 -CTGAT GAGTCCGTGAGGACGAAA-3 0 ) was labelled with [g- 
Metabolic labelling and immunoprecipitation
Transfected cells were incubated on 6-cm dishes in methionine-free DMEM medium (Invitrogen s ) for 1 h, and then labelled for 16 h with 50 mCi [ 35 S]methionine (Amersham Pharmacia) in a medium containing 4% dialyzed FCS. M6PR300 was immunoprecipitated from extracts of cells as described for M6PR46 with antisera against rat M6PR300.
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The antiserum crossreacts with mouse M6PR300 and was kindly provided by K von Figura.
The quantitation of Northern blots and immunoprecipitations were performed using a phosphoimager BAS 1000 (Fuji).
Arylsulfatase A activity determination MEF-mpr46 cells were lysed 48 h after transfection. Human ASA was immunoprecipitated from the media and the cell homogenates with a monoclonal antibody against hASA.
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Human ASA activity in medium and homogenate was measured with 200 ml substrate solution consisting 10 mM p-nitrocatecholsulfate in 170 mM NaCl, 0.5 M sodium acetate (pH 5.0), 0.3% Triton X-100 and 1 mg/ ml BSA. Reaction was performed at 371C for 90 min and stopped with 1 M NaOH. Absorption was read at 515 nm.
